11月2日 - Belite Bio Inc.宣布,英国药品和健康产品监管局(MHRA)已同意其基于中期分析结果提出的有条件市场授权申请,以使用Tinlarebant治疗Stargardt病。
11月2日 - Belite Bio Inc.宣布,英国药品和健康产品监管局(MHRA)已同意其基于中期分析结果提出的有条件市场授权申请,以使用Tinlarebant治疗Stargardt病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.